vs
Side-by-side financial comparison of Axsome Therapeutics, Inc. (AXSM) and UL Solutions Inc. (ULS). Click either name above to swap in a different company.
UL Solutions Inc. is the larger business by last-quarter revenue ($340.0M vs $191.2M, roughly 1.8× Axsome Therapeutics, Inc.). On growth, Axsome Therapeutics, Inc. posted the faster year-over-year revenue change (57.4% vs -12.4%). Over the past eight quarters, Axsome Therapeutics, Inc.'s revenue compounded faster (48.1% CAGR vs -31.8%).
Jazz Pharmaceuticals plc is a global biopharmaceutical company with a focus on oncology and neuroscience. It was founded in 2003 in California, United States and is now headquartered in Dublin, Ireland.
The UL enterprise is a global private safety company headquartered in Northbrook, Illinois, composed of three organizations, UL Research Institutes, UL Standards & Engagement and UL Solutions.
AXSM vs ULS — Head-to-Head
Income Statement — Q1 FY2026 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $191.2M | $340.0M |
| Net Profit | — | — |
| Gross Margin | — | — |
| Operating Margin | -33.1% | 24.4% |
| Net Margin | — | — |
| Revenue YoY | 57.4% | -12.4% |
| Net Profit YoY | — | — |
| EPS (diluted) | — | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $191.2M | $340.0M | ||
| Q4 25 | $196.0M | $789.0M | ||
| Q3 25 | $171.0M | $783.0M | ||
| Q2 25 | $150.0M | $776.0M | ||
| Q1 25 | $121.5M | $705.0M | ||
| Q4 24 | $118.8M | $739.0M | ||
| Q3 24 | $104.8M | $731.0M | ||
| Q2 24 | $87.2M | $730.0M |
| Q1 26 | — | — | ||
| Q4 25 | $-28.6M | $67.0M | ||
| Q3 25 | $-47.2M | $100.0M | ||
| Q2 25 | $-48.0M | $91.0M | ||
| Q1 25 | $-59.4M | $67.0M | ||
| Q4 24 | $-74.9M | $81.0M | ||
| Q3 24 | $-64.6M | $88.0M | ||
| Q2 24 | $-79.3M | $101.0M |
| Q1 26 | — | — | ||
| Q4 25 | — | 49.7% | ||
| Q3 25 | — | 50.3% | ||
| Q2 25 | — | 49.4% | ||
| Q1 25 | — | 48.4% | ||
| Q4 24 | — | 47.4% | ||
| Q3 24 | — | 49.0% | ||
| Q2 24 | — | 50.1% |
| Q1 26 | -33.1% | 24.4% | ||
| Q4 25 | -13.8% | 15.0% | ||
| Q3 25 | -27.0% | 19.9% | ||
| Q2 25 | -24.5% | 17.9% | ||
| Q1 25 | -46.9% | 15.5% | ||
| Q4 24 | -61.1% | 15.6% | ||
| Q3 24 | -59.8% | 17.8% | ||
| Q2 24 | -89.5% | 17.3% |
| Q1 26 | — | — | ||
| Q4 25 | -14.6% | 8.5% | ||
| Q3 25 | -27.6% | 12.8% | ||
| Q2 25 | -32.0% | 11.7% | ||
| Q1 25 | -48.9% | 9.5% | ||
| Q4 24 | -63.1% | 11.0% | ||
| Q3 24 | -61.7% | 12.0% | ||
| Q2 24 | -91.0% | 13.8% |
| Q1 26 | — | — | ||
| Q4 25 | $-0.55 | $0.33 | ||
| Q3 25 | $-0.94 | $0.49 | ||
| Q2 25 | $-0.97 | $0.45 | ||
| Q1 25 | $-1.22 | $0.33 | ||
| Q4 24 | $-1.54 | $0.40 | ||
| Q3 24 | $-1.34 | $0.44 | ||
| Q2 24 | $-1.67 | $0.50 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $305.1M | — |
| Total DebtLower is stronger | $70.0M | — |
| Stockholders' EquityBook value | — | — |
| Total Assets | $713.6M | — |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $305.1M | — | ||
| Q4 25 | $322.9M | $295.0M | ||
| Q3 25 | $325.3M | $255.0M | ||
| Q2 25 | $303.0M | $272.0M | ||
| Q1 25 | $300.9M | $267.0M | ||
| Q4 24 | $315.4M | $298.0M | ||
| Q3 24 | $327.3M | $327.0M | ||
| Q2 24 | $315.7M | $295.0M |
| Q1 26 | $70.0M | — | ||
| Q4 25 | — | $491.0M | ||
| Q3 25 | — | $544.0M | ||
| Q2 25 | — | $608.0M | ||
| Q1 25 | — | $653.0M | ||
| Q4 24 | — | $742.0M | ||
| Q3 24 | — | $797.0M | ||
| Q2 24 | — | $810.0M |
| Q1 26 | — | — | ||
| Q4 25 | $88.3M | $1.3B | ||
| Q3 25 | $73.7M | $1.2B | ||
| Q2 25 | $73.1M | $1.1B | ||
| Q1 25 | $53.2M | $970.0M | ||
| Q4 24 | $57.0M | $904.0M | ||
| Q3 24 | $92.9M | $872.0M | ||
| Q2 24 | $102.9M | $769.0M |
| Q1 26 | $713.6M | — | ||
| Q4 25 | $689.8M | $2.9B | ||
| Q3 25 | $669.3M | $2.9B | ||
| Q2 25 | $639.8M | $2.9B | ||
| Q1 25 | $596.7M | $2.9B | ||
| Q4 24 | $568.5M | $2.8B | ||
| Q3 24 | $561.5M | $2.9B | ||
| Q2 24 | $548.2M | $2.7B |
| Q1 26 | — | — | ||
| Q4 25 | — | 0.39× | ||
| Q3 25 | — | 0.46× | ||
| Q2 25 | — | 0.56× | ||
| Q1 25 | — | 0.67× | ||
| Q4 24 | — | 0.82× | ||
| Q3 24 | — | 0.91× | ||
| Q2 24 | — | 1.05× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AXSM
| Product sales, net | $189.4M | 99% |
| Royalty revenue and milestone revenue | $1.8M | 1% |
ULS
Segment breakdown not available.
